Free trial of Company Profiling

Discover first hand how profiling with Pharmalicensing can take your business development activities to the next level with a free 30-day risk free trial.

You will have the full functionality of the company profiling service, allowing you to receive targeted enquiries for up to 1 in-licensing and 1 out-licensing opportunity.

In less than 5 minutes**, you can have your company and licensing profiles viewable by our audience of over 100,000 business development personnel worldwide.

Case Studies - See what others think about our service.

Why you should take a trial:

• 30-day trial absolutely free with no commitment to continue once the trial has ended
• receive valuable global industry contacts from interested parties directly to your inbox
• source more or alternative potential partners for your products
• increase your chance of finding the perfect partner
• no risk to yourself, Pharmalicensing bears the total cost of the trial. Only pay if you wish to subscribe for a full 12-month period!

Frequently asked questions about the trial:

Why do I need to submit an application for a free trial?
To ensure the high quality of the information found on Pharmalicensing is maintained, we are required to validate your information prior to authorizing a trial. You will be notified once your application has been accepted but this is typically no more than 1 working day.

When does the trial start?
Your trial will start once your application for a free trial has been accepted. You will then have the full functionality of profiling for 30 days from this point. It is your responsibility to publish your own information within this time period. You are unable to have more than one trial period per company even if you don't put any information on to the website.

How do I add my information?
Once you have submitted your request for a free 30-day trial, you will be able to download full documentation instructing you on how to upload your information.

What happens at the end of the 30 day trial?
This is up to you. If you have found that you are receiving high quality enquiries regarding your licensing requirements and wish to continue for the next 12 months, let us know and we will setup a subscription for you. Please see the comparison table for subscription options and pricing. If you do not wish to continue, then the trial will automatically terminate after 30 days and no further fees will be due.

What information will I receive from interested parties?
This varies greatly dependent on the nature of the enquiry, however, you will definitely receive a contact name, telephone number and email address.

Will I receive SPAM email?
No - Pharmalicensing has introduced several methods for ensuring that as little SPAM is sent through the system as possible. In the unlikely event that you do receive any contact from people that are not true industry contacts, then please contact Pharmalicensing immediately to ensure that the offending party is removed.

How long will the trial be available for?
The trial is for a limited period only. Take your trial early to ensure you are eligible.

Terms & Conditions
Please see our terms and conditions for trial subscribers for full subscription T&C's.

* Costs, excluding success-based application of Lehman Formula
Lehman Formula: A compensation formula developed by Lehman brothers for transaction based services
- 5% of the first million dollars involved in the transaction
- 4% of the second million
- 3% of the third million
- 2% of the fourth million
- 1% of everything thereafter (above 4 million dollars)

** Once your trial application has been approved

^† Discount available for universities

Apply now!

To activate your trial simply follow our fully automated company profile activation process and your company will be visible to our audience in less than 5 minutes.**

Buy now!

1-3 licensing opportunities
Level 1 - $3350*
Level 1+ - $4350*

4-6 licensing opportunities
Level 2 - $4250*
Level 2+ - $5250*

7+ licensing opportunities
Level 3 - $5500*†

See our comparison table for more information.